Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.

Gynecologic oncology·2026
Same author

Depth of response to primary POMB/ACE chemotherapy predicts survival in poor prognosis germ-cell tumours.

British journal of cancer·2026
Same author

Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Comparison of efficacy and toxicity of 2 dactinomycin (ACTD) regimens in the second-line treatment of low-risk gestational trophoblastic neoplasia: a retrospective study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study.

BMC medical research methodology·2026
Same author

Primary Uterine Nongestational Placental Site Trophoblastic Tumor as a Distinct Entity: A Report of 5 Cases.

The American journal of surgical pathology·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay
10:28

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay

Published on: January 8, 2012

Gestational trophoblastic disease.

Michael J Seckl1, Neil J Sebire, Ross S Berkowitz

  • 1Department of Cancer Medicine, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, London, UK. m.seckl@imperial.ac.uk

Lancet (London, England)
|August 3, 2010
PubMed
Summary
This summary is machine-generated.

Gestational trophoblastic disease (GTD) management has advanced significantly, achieving over 98% cure rates for malignant forms. Effective treatments, biomarker use, and centralized care have dramatically improved outcomes for women with these rare tumors.

More Related Videos

Derivation of Mouse Trophoblast Stem Cells from Blastocysts
10:19

Derivation of Mouse Trophoblast Stem Cells from Blastocysts

Published on: June 8, 2010

Related Experiment Videos

Last Updated: Jun 10, 2026

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay
10:28

Isolation of Primary Mouse Trophoblast Cells and Trophoblast Invasion Assay

Published on: January 8, 2012

Derivation of Mouse Trophoblast Stem Cells from Blastocysts
10:19

Derivation of Mouse Trophoblast Stem Cells from Blastocysts

Published on: June 8, 2010

Area of Science:

  • Gynecology
  • Oncology
  • Reproductive Medicine

Background:

  • Gestational trophoblastic disease (GTD) includes premalignant hydatidiform moles and malignant GT tumors like choriocarcinoma.
  • Historically, malignant GTD had high mortality rates.

Purpose of the Study:

  • To summarize current management strategies for GTD.
  • To discuss controversies and future research in GTD.

Main Methods:

  • Review of management and follow-up protocols for GTD.
  • Analysis of factors contributing to improved cure rates.

Main Results:

  • Current management protocols achieve over 98% cure rates for GTD.
  • Effective treatments, human chorionic gonadotropin (hCG) as a biomarker, and centralized care are key to success.

Conclusions:

  • Modern management has transformed GTD outcomes, enabling high cure rates and fertility preservation.
  • Continued research and centralized care are vital for further advancements.